Navigation Links
TGen presents lung cancer studies at Amsterdam conference
Date:7/7/2011

PHOENIX, Ariz. July 7, 2011 The Translational Genomics Research Institute (TGen) is presenting two key studies, including one today, at the 14th World Conference on Lung Cancer, July 3-7 in Amsterdam.

One study, presented July 4, involved a gene called GLI1, which may limit the effectiveness of the most common combination chemotherapy given to patients with small cell lung cancer (SCLC).

Another study, presented today, July 7, suggests that combination drug therapy may be needed to combat non-small cell lung cancer (NSCLC) the more common type of lung cancer when patients have elevated levels of a protein called JAK2.

Both studies will be presented at the Amsterdam conference, which is sponsored by the International Association for the Study of Lung Cancer (IASLC). The association hosts an international lung cancer meeting every two years. Both studies also will be published in a special supplement of the Journal of Thoracic Oncology.

GLI1 may compromise chemotherapy

In the study involving GLI1, laboratory tests of six SCLC cell lines showed that GLI1 can play an important role in resistance to the drugs cisplatin and etoposide, which given together are the standard first-line chemotherapy for SCLC.

"Resistance to chemotherapeutic drugs is particularly crippling in SCLC," said Dr. Glen Weiss, Co-Unit Head of TGen's Lung Cancer Research Laboratory, who led the research in both studies presented at the conference. "We are optimistic that this GLI1 study will lead to more detailed examinations that will provide a better way of treating patients."

Next steps include using RNA interference tests to validate the role of GLI1 and several related genes along the Hedgehog Signaling Pathway a series of chemical reactions within a cell. The Hedgehog pathway contains genes that lead to GLI1, a known tumor-promoting gene. Weiss' team also plans to conduct tests on actual tumors from SCLC patients.

VARI joins TGen in JAK2 study

The Van Andel Research Institute (VARI), TGen's affiliate in Grand Rapids, Mich., joined TGen in conducting the JAK2 study.

The JAK2 protein can activate the gene called STAT3, part of a family of genes that provide instructions for making proteins that are part of the essential chemical signaling pathways that control growth and development in cells. STAT3 has been found to be overactive in cases of several types of cancer, including breast, prostate, pancreas, leukemia and lymphoma.

In laboratory tests involving seven NSCLC cell lines, the TGen-VARI study found that STAT3 was activated in some cell lines by JAK2, independent of key oncogenic, or cancer-causing mutations.

"JAK2-STAT3 signaling plays crucial roles in tumor-cell behavior that may not be effectively inhibited by drugs that selectively target these mutations," Dr. Weiss said. "This suggests that there may be a potential role for combination therapy, so you have a better chance of knocking out a NSCLC tumor, or keeping it at bay."

Dr. Jeff MacKeigan, Head of VARI's Laboratory of Systems Biology, said this yearlong study, funded by a TGen-VARI integration grant, should benefit future lung cancer research because of the study's clinically annotated tissue microarray.

"Our human tumor samples may be used for meaningful exploratory research on other key signaling pathways in NSCLC," MacKeigan said.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology news :

1. Ben-Gurion University team presents environment movement report to Israels Knesset
2. Louisiana Tech researcher presents on eco-friendly nanotechnology at national conference
3. KIT presents innovations at the 2011 Hannover Messe
4. 23andMe presents top 10 most interesting genetic findings of 2010
5. Colossal fossil: Museums new whale skeleton represents decades of research
6. UC doctoral student presents research at international conference
7. American Society of Agronomy presents 2010 Fellows
8. AMP presents at FDA meeting on regulating diagnostics
9. AAPS presents therapeutic protein drug interactions workshop
10. ASNTR meeting presents Sanberg Awards to Prof. Lin & Prof. Dunnett
11. Latino Theater Company Presents Dementia Starting April 29
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... , April 11, 2017 No ... but researchers at the New York University Tandon ... of Engineering have found that partial similarities between ... systems used in mobile phones and other electronic ... The vulnerability lies in the fact ...
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life Sciences ... the life sciences and healthcare industries, announces a presentation by Subbu Viswanathan and ... presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach ...
(Date:10/9/2017)... ... October 09, 2017 , ... The ... medical marijuana products targeting the needs of consumers who are incorporating medical marijuana ... place in Phoenix, Arizona. , As operators of two successful Valley dispensaries, The ...
Breaking Biology Technology: